Thomas Christensen outlines some of his lessons learned for first time OPDP submissions, promotional material, and labelling.
Jeff R. Livingstone outlines the critical steps necessary to ensure an agile, responsive and streamlined supply chain.
While it is foundational to commercial operations, most European life sciences companies are not getting what they need from their customer data, writes Guillame Roussel.
In-market experimentation is the best way to address the challenge of pitching brand leaders on new ways to reach their target population through digital and other non-personal channels, write Scott Beauchamp and Michael Calamari.
As pricing transparency regulations and COVID-19 accelerate market disruption and changes in consumer behavior demand new engagement models, how can your organization prepare for the powerful shift toward more consumer-centric pricing transparency?
Experts debate the practice’s rise up the life sciences agenda.
We know deregulation is coming, although we do not know what it will look like. The one looming question for pharmaceutical and medical device companies is about the future of compliance and regulations.
Pilot study affirms the value of a standards-based solution for prescription drug traceability-and the need to start now to meet compliance deadlines for the Drug Supply Chain Security Act.
Curing cancer is not an impossibility anymore. Essential to any effort to achieve this will be the policies coming from President Trump’s administration, writes James Nathanielsz.
China's healthcare reforms are generating uncertainty for its domestic pharmaceutical market, writes Jon Zifferblatt.
Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
Pharma must develop digital identity strategies for creating seamless, safe and compliant customer journeys, writes Jamie Beckland.
An overview of marketing during the COVID-19 crisis and how to utilize various tactical solutions to successfully reach your targeted healthcare professional audiences.
It’s no longer sufficient for a pharma to develop better products or even build simple apps. The industry increasingly needs to create sophisticated predictive algorithms to maximize the ability of its products, write Tom Agan and Fred Geyer.
Michelle Maskaly and Christen Harm speak with Bill Carson, President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Kabir Nath, President & CEO of Otsuka North America Pharmaceuticals about digital medicine, mental health therapies, and creating a smooth and collaborative relationship between R&D and commercial.
Study examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
Study examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
Study examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
Study examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
For pharma, diagnosing what ails or strengthens performance in this critical corporate discipline may help reshape business prognosis.
Janice Kranz, co-founder of Eikonizo Therapeutics, bring us up to date on how targeting tau to fight Alzheimer’s and other neurodegenerative diseases is making waves in the CNS space.
This year, data curation will become as important as document authoring and sit at the core of companies that are nimbly adjusting to an ever-changing marketplace, writes John Lawrie.